Beam Therapeutics Stock Soars 11.8%, Hits Intraday High of $25.12

Beam Therapeutics, Inc. has experienced a significant surge in its stock price, gaining 11.8% on September 18, 2025. The stock reached an intraday high of USD 25.12, marking a notable performance in the pharmaceuticals and biotechnology sector.
In terms of performance metrics, Beam Therapeutics has shown a remarkable 38.14% increase over the past day, significantly outperforming the S&P 500, which recorded a slight decline of 0.1%. Over the past week, the stock has risen by 48.7%, while its monthly performance stands at 44.17%. However, the company has faced challenges over the longer term, with a 1-year performance of just 2.87% compared to the S&P 500's 17.14%.

Despite the recent uptick, Beam Therapeutics has reported negative results for the last three consecutive quarters, with a net profit of USD -306.36 million and a decline in net sales. The company's market capitalization is approximately USD 2,017 million, placing it in the small-cap category. As it navigates these financial dynamics, Beam Therapeutics continues to be a focal point in the biotechnology landscape.